# Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

> **NCT02588677** · PHASE2,PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 394 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Masitinib (4.5)
- **DRUG:** Riluzole
- **DRUG:** Placebo
- **DRUG:** Masitinib (3.0)

## Key facts

- **NCT ID:** NCT02588677
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-12-05
- **Final completion:** 2018-03
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588677, "Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02588677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*